Pagibaximab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Pagibaximab ?
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target staphylococcal lipoteichoic acid
Clinical data
Legal status ?
Identifiers
CAS number 595566-61-3 N
ATC code None
Chemical data
Formula C6462H9996N1728O2028S54 
 N (what is this?)  (verify)

Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010, it is undergoing Phase II/III clinical trials.[1][2]

References[edit]